Baxter International Inc (BAX)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $13.35B
Last updated: Nov 17, 2026 at 11:05 AM ET
Baxter International Inc (BAX) Earnings: Report Dates and Results
Baxter International (BAX) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Baxter International reported EPS of $0.58, above the $0.51 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BAX has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 36.4% above the $0.44 reported for the quarter ended Dec 31, 2025.
BAX Earnings Call
The latest BAX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BAX beat 31, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $2.98B, up 5.3% from $2.83B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.58 | $0.51 | $0.50 - $0.54 | +13.73% | Beat | -15.9% | 13 | 2 up, 7 down | Oct 29, 2026 | $2.98B |
| Jun 30, 2026 | $0.56 | $0.36 | $0.36 - $0.38 | +55.56% | Beat | -5.1% | 11 | N/A | Jul 30, 2026 | $2.96B |
| Mar 31, 2026 | $0.36 | $0.31 | $0.26 - $0.34 | +16.13% | Beat | -34.5% | 12 | 1 up, 2 down | Apr 30, 2026 | $2.70B |
| Dec 31, 2025 | $0.44 | $0.54 | $0.52 - $0.56 | -18.52% | Miss | -24.1% | 14 | 1 up, 1 down | Feb 12, 2026 | $2.97B |
| Sep 30, 2025 | $0.69 | $0.60 | $0.58 - $0.61 | +15.00% | Beat | +40.8% | 13 | 1 up, 0 down | Oct 30, 2025 | $2.83B |
| Jun 30, 2025 | $0.59 | $0.61 | $0.59 - $0.64 | -3.28% | Miss | -13.2% | 12 | 1 up, 0 down | Jul 31, 2025 | $2.81B |
| Mar 31, 2025 | $0.55 | $0.48 | $0.48 - $0.49 | +14.58% | Beat | -15.4% | 12 | 1 up, 0 down | May 1, 2025 | $2.63B |
| Dec 31, 2024 | $0.58 | $0.52 | $0.51 - $0.53 | +11.54% | Beat | -34.1% | 10 | 1 up, 1 down | Feb 20, 2025 | $2.75B |
| Sep 30, 2024 | $0.49 | $0.78 | $0.77 - $0.78 | -37.18% | Miss | -27.9% | 13 | 0 up, 0 down | Nov 8, 2024 | $2.70B |
| Jun 30, 2024 | $0.68 | $0.66 | $0.60 - $0.68 | +3.03% | Beat | +23.6% | 14 | 0 up, 0 down | Aug 6, 2024 | $2.69B |
| Mar 31, 2024 | $0.65 | $0.61 | $0.59 - $0.62 | +6.56% | Beat | +10.2% | 13 | 0 up, 0 down | May 2, 2024 | $2.49B |
| Dec 31, 2023 | $0.88 | $0.86 | $0.85 - $0.88 | +2.33% | Beat | 0.0% | 13 | 0 up, 0 down | Feb 8, 2024 | $541.00M |
| Sep 30, 2023 | $0.68 | $0.68 | $0.66 - $0.79 | 0.00% | In line | -17.1% | 11 | 1 up, 0 down | Nov 2, 2023 | $2.60B |
| Jun 30, 2023 | $0.55 | $0.60 | $0.60 - $0.67 | -8.33% | Miss | -36.8% | 13 | 1 up, 0 down | Jul 27, 2023 | $3.71B |
| Mar 31, 2023 | $0.59 | $0.49 | $0.47 - $0.58 | +20.41% | Beat | -36.6% | 13 | 0 up, 0 down | Apr 27, 2023 | $3.51B |
| Dec 31, 2022 | $0.88 | $0.94 | $0.91 - $0.96 | -6.38% | Miss | -15.4% | 13 | 0 up, 1 down | Feb 9, 2023 | N/A |
| Sep 30, 2022 | $0.82 | $0.81 | $0.79 - $0.87 | +1.23% | Beat | -19.6% | 14 | 0 up, 1 down | Oct 27, 2022 | $3.61B |
| Jun 30, 2022 | $0.87 | $0.87 | $0.85 - $0.89 | 0.00% | In line | +8.7% | 12 | 0 up, 0 down | Jul 28, 2022 | $3.59B |
| Mar 31, 2022 | $0.93 | $0.81 | $0.75 - $0.82 | +14.81% | Beat | +22.4% | 13 | 0 up, 1 down | Apr 28, 2022 | $3.71B |
| Dec 31, 2021 | $1.04 | $1.03 | $0.97 - $1.08 | +0.97% | Beat | +30.0% | 15 | 0 up, 0 down | Feb 17, 2022 | $2.88B |
| Sep 30, 2021 | $1.02 | $0.94 | $0.93 - $0.96 | +8.51% | Beat | +22.9% | 16 | N/A | Oct 28, 2021 | $3.23B |
| Jun 30, 2021 | $0.80 | $0.75 | $0.73 - $0.81 | +6.67% | Beat | +25.0% | 16 | N/A | Jul 29, 2021 | $3.10B |
| Mar 31, 2021 | $0.76 | $0.65 | $0.63 - $0.68 | +16.92% | Beat | -7.3% | 16 | N/A | Apr 29, 2021 | $2.95B |
| Dec 31, 2020 | $0.80 | $0.76 | $0.73 - $0.82 | +5.26% | Beat | -17.5% | 16 | N/A | Feb 4, 2021 | $3.18B |
| Sep 30, 2020 | $0.83 | $0.72 | $0.69 - $0.76 | +15.28% | Beat | +12.2% | 16 | N/A | Oct 29, 2020 | $2.97B |
| Jun 30, 2020 | $0.64 | $0.71 | $0.63 - $0.82 | -9.86% | Miss | -28.1% | 16 | N/A | Jul 30, 2020 | $2.72B |
| Mar 31, 2020 | $0.82 | $0.72 | $0.69 - $0.75 | +13.89% | Beat | +7.9% | 14 | N/A | Apr 30, 2020 | $2.80B |
| Dec 31, 2019 | $0.97 | $0.88 | $0.83 - $0.93 | +10.23% | Beat | +24.4% | 13 | N/A | Mar 17, 2020 | $3.04B |
| Sep 30, 2019 | $0.74 | $0.84 | N/A | -11.90% | Miss | -7.5% | N/A | N/A | Oct 24, 2019 | $2.85B |
| Jun 30, 2019 | $0.89 | $0.81 | $0.80 - $0.83 | +9.88% | Beat | +15.6% | 17 | N/A | Jul 25, 2019 | $2.83B |
| Mar 31, 2019 | $0.76 | $0.68 | $0.67 - $0.72 | +11.76% | Beat | +8.6% | 16 | N/A | Apr 25, 2019 | $2.64B |
| Dec 31, 2018 | $0.78 | $0.73 | $0.71 - $0.75 | +6.85% | Beat | +21.9% | 17 | N/A | Jan 31, 2019 | $2.82B |
| Sep 30, 2018 | $0.80 | $0.74 | $0.73 - $0.75 | +8.11% | Beat | +25.0% | 16 | N/A | Oct 31, 2018 | $2.76B |
| Jun 30, 2018 | $0.77 | $0.71 | $0.70 - $0.73 | +8.45% | Beat | +22.2% | 15 | N/A | Jul 26, 2018 | $2.84B |
| Mar 31, 2018 | $0.70 | $0.62 | $0.61 - $0.65 | +12.90% | Beat | +20.7% | 15 | N/A | Apr 26, 2018 | $2.68B |
| Dec 31, 2017 | $0.64 | $0.59 | $0.57 - $0.62 | +8.47% | Beat | +12.3% | 14 | N/A | Feb 1, 2018 | $2.80B |
| Sep 30, 2017 | $0.64 | $0.59 | $0.56 - $0.60 | +8.47% | Beat | +14.3% | 16 | N/A | Oct 25, 2017 | $2.71B |
| Jun 30, 2017 | $0.63 | $0.57 | $0.55 - $0.59 | +10.53% | Beat | +37.0% | 16 | N/A | Jul 26, 2017 | $2.60B |
| Mar 31, 2017 | $0.58 | $0.51 | N/A | +13.73% | Beat | +61.1% | N/A | N/A | Apr 26, 2017 | $2.48B |
| Dec 31, 2016 | $0.57 | $0.52 | N/A | +9.62% | Beat | +32.6% | N/A | N/A | Feb 1, 2017 | $2.65B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.27, down 5.4% from the year before. It was $1.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.27 | -5.4% |
| Dec 31, 2024 | $2.40 | -11.1% |
| Dec 31, 2023 | $2.70 | -22.9% |
| Dec 31, 2022 | $3.50 | -3.3% |
| Dec 31, 2021 | $3.62 | +17.2% |
| Dec 31, 2020 | $3.09 | -8.0% |
| Dec 31, 2019 | $3.36 | +10.2% |
| Dec 31, 2018 | $3.05 | +22.5% |
| Dec 31, 2017 | $2.49 | +27.7% |
| Dec 31, 2016 | $1.95 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,836 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,284 | 14 | |
| 2026Q1 | Mar 31, 2026 | 8,333 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,445 | 12 | |
| 2025Q3 | Sep 30, 2025 | 7,816 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,708 | 11 | |
| 2025Q1 | Mar 31, 2025 | 7,033 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,169 | 12 |
2026Q3 Earnings Call
Opening remarks
Kevin Moran Vice President, Investor Relations Good morning, and welcome. Today, we'll discuss Baxter's third quarter results, along with our updated financial outlook for the full year 2026. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website. Joining me today are Andrew Hider, President and Chief Executive Officer; and John Rogers, Executive Vice President and Chief Financial Officer. During the call, we will be making forward-looking statements, including comments regarding our updated financial outlook for the full year 2026 and the anticipated drivers of the fourth quarter, the anticipated impact of various regulatory, operational and quality matters, including ones related to our infusion pump platform and ongoing supply challenges, and commentary regarding the global macroeconomic environment, including tariff impacts and the broader inflationary pressures. Forward-looking statements involve risks and uncertainties, which could cause our actual results to differ materially from our current expectations. Please refer to today's press release, the forward-looking statement slide at the beginning of our investor presentation and our SEC filings for more detail. In addition, please note, on the call, all of our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. Non-GAAP financial measures are used to help investors understand Baxter's ongoing business performance. GAAP to non-GAAP reconciliations can be found in the schedules attached to our press release and our earnings presentation. On the call, we will reference organic growth, which excludes the impact of foreign exchange, MSA revenues from Vantive and impacts associated with business acquisitions or divestitures. Unless otherwise noted, all financial results on today's call reflect continuing operations and exclude Baxter's former Kidney Care business, which is reported as discontinued operations. Finally, Andrew, John and I will take questions following the prepared remarks, and we kindly ask that you limit yourself to one question and one brief follow-up so that we can give as many people in the queue an opportunity. With that, I'd like to turn the call over to Andrew.
Andrew Hider President and Chief Executive Officer Thank you, Kevin, and good morning, everyone. Before discussing the quarter, I want to welcome John Rogers to Baxter as our new Chief Financial Officer. John joined us on October 1 and has a strong track record of leading multiple complex organizations through transformation and performance improvement. His deep financial and operational experience aligns well with our strategic priorities, and I look forward to partnering with him as we continue to advance our turnaround. Now I will turn to the quarter. Our third quarter performance provides further evidence that our turnaround is gaining traction.
Frequently Asked Questions About BAX
When is Baxter International's next earnings date?
Baxter International's next earnings report is expected for Feb 10, 2027.
Did BAX beat earnings estimates last quarter?
Yes. Baxter International reported EPS of $0.58 for the quarter ended Sep 30, 2026, above the $0.51 estimate, a 13.73% surprise.
What EPS do analysts expect from BAX next quarter?
The consensus EPS estimate for Baxter International for the quarter ending Dec 31, 2026 is $0.60 from 15 analysts, with estimates from $0.56 to $0.64.
How often does BAX beat earnings estimates?
Baxter International beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +13.09%.
BAX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors